Romeo Maciuca

3.8k citations

29 papers · 2.5k indexed · 1 hit paper · h-index 13

Impact in

Rheumatology top 0.5%
- Systemic Lupus Erythematosus Research
Immunology top 2%
- T-cell and B-cell Immunology
- Atherosclerosis and Cardiovascular Diseases
- Immune Cell Function and Interaction

Papers in

Immunology and Allergy 7
- Allergic Rhinitis and Sensitization 5
Rheumatology 8
- Systemic Lupus Erythematosus Research 8

Co-authors: Paul Brunetta Richard Furie Brad H. Rovin Fernando C. Fervenza Gerald B. Appel Jorge Sánchez‐Guerrero Jay Garg R. John Looney
Journals: Annals of the Rheumatic Diseases (3 papers)Journal of Crohn s and Colitis (3 papers)Gastroenterology (3 papers)Neurology (2 papers)The American Journal of Gastroenterology (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Romeo Maciuca

27 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study 2012 · 972 citations

Peers

Countries citing papers authored by Romeo Maciuca

Since Specialization

Citations

This map shows the geographic impact of Romeo Maciuca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Romeo Maciuca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Romeo Maciuca more than expected).

Fields of papers citing papers by Romeo Maciuca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Romeo Maciuca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Romeo Maciuca. The network helps show where Romeo Maciuca may publish in the future.

Co-authors

The 25 scholars most cited alongside Romeo Maciuca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Romeo Maciuca Line = papers co-authored together Romeo Maciuca links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Metabolomic Profiling of Plasma Samples from PPMI Identifies Molecular Signatures of Parkinson’s Disease and Genetic Parkinson’s Disease Susceptibility (P3-11.011) Neurology ·Sarah Huntwork‐Rodriguez, Jung H. Suh, Grace F. Crotty, Romeo Maciuca, Eric A. Macklin, Sonnet S. Davis, Khuldoon Usman, Rachit Bakshi, Xiqun Chen, Samantha Molsberry, Alberto Ascherio, Michael A. Schwarzschild	2023	0
2	Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10 Scientific Reports ·Rong Qiu Xue, Y. S. Shareef, Michael T. Maloney, Vitaliy V. Bondar, Shan V. Andrews, А. Донской, Ceyda Llapashtica, Romeo Maciuca, Hoang N. Nguyen, Hilda Solanoy, Annie Arguello, Laralynne Przybyla, Nathan J. Moerke, Sarah Huntwork‐Rodriguez, Anastasia G. Henry	2021	29
3	Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury Clinical Pharmacology & Therapeutics ·Michael E. Rothenberg, Yehong Wang, Annemarie Lekkerkerker, Dimitry M. Danilenko, Romeo Maciuca, Rich Erickson, Ann Herman, Eric Stefanich, Timothy T. Lu	2018	53
4	PWE-071 Etrolizumab induction in moderate/severe anti-TNF intolerant/refractory (IR) UC: the hickory open-label induction (OLI) trial Bu Hayee, David T. Rubin, Brian G. Feagan, Young S. Oh, Udayasankar Arulmani, Helen E.J. Tyrrell, Romeo Maciuca, Sarah Williams, Swati Tole, James Thommes, Leslie Harrison	2018	1
5	20 ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT Gastroenterology ·Laurent Peyrin‐Biroulet, David T. Rubin, Brian Feagan, Young S. Oh, Udayasankar Arulmani, Helen E.J. Tyrrell, Romeo Maciuca, Sarah Williams, Swati Tole, James Thommes	2018	4
6	P395 Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS) Journal of Crohn s and Colitis ·William J. Sandborn, Stefan Schreiber, Meina Tang, Ritsu Nomura, Young S. Oh, Romeo Maciuca	2017	3
7	Etrolizumab Treatment Improves Histological Activity as Assessed by the Robarts Histopathology Index Gastroenterology ·Brian G. Feagan, Gert De Hertogh, Laurent Peyrin‐Biroulet, David T. Rubin, Romeo Maciuca, Jacqueline McBride, Udayasankar Arulmani, Alexis Scherl	2017	1
8	Etrolizumab Treatment Leads to Early Improvement in Symptoms and Inflammatory Biomarkers in Anti-TNF-refractory Patients in the Open-Label Induction Cohort of the Phase 3 Hickory Study Gastroenterology ·Laurent Peyrin‐Biroulet, Brian G. Feagan, John Mansfield, David T. Rubin, Udayasankar Arulmani, Romeo Maciuca, Helen E.J. Tyrrell, James Thommes, Swati Tole	2017	4
9	OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Brian G. Feagan, John Mansfield, David T. Rubin, Udayasankar Arulmani, Romeo Maciuca, Helen E.J. Tyrrell, James Thommes, Swati Tole	2017	6
10	A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma Respiratory Research ·Jeffrey M. Harris, Romeo Maciuca, Mary S. Bradley, Christopher R. Cabanski, Heleen Scheerens, Jeremy J. Lim, Fang Cai, Ronald Campbell Smith, X. Charlene Liao, Divya Samineni, Rui Zhu, O Blétry, Weily Soong, Joseph D. Diaz, Iyad Suleiman, Mohamed Arafath Saucedo Yunis, Dimo Dimov, Ioana Agache, Steven G. Kelsen	2016	73
11	A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) Annals of the Rheumatic Diseases ·Kenneth Kalunian, Joan T. Merrill, Romeo Maciuca, Jacqueline McBride, Michael J. Townsend, Xiaohui Wei, John C. Davis, William P. Kennedy	2015	275
12	Etrolizumab Treatment Does Not Modify Levels of VCAM-1 in Ulcerative Colitis Patients The American Journal of Gastroenterology ·Franklin Fuh, 哲生山下, Yila Ma, Rich Erickson, Romeo Maciuca, Meina Tang, Mary Keir, Séverine Vermeire, Sharon O’Byrne, Teresa Ramirez‐Montagut	2015	1
13	Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies Thorax ·Nicola A. Hanania, Michael Noonan, Jonathan Corren, Phillip E. Korenblat, Yanan Zheng, Saloumeh K Fischer, Melissa Cheu, Wendy S. Putnam, Elaine Murray, Heleen Scheerens, Cécile Holweg, Romeo Maciuca, Sarah Gray, Ramona L. Doyle, Dana McClintock, Julie Olsson, John G. Matthews, Karl Yen	2015	299
14	Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE Lupus Science & Medicine ·William P. Kennedy, Romeo Maciuca, Kristen Wolslegel, Yila Ma, Alexander R. Abbas, Christina Chaivorapol, Alyssa Morimoto, Jacqueline McBride, 順子田中, Bruce C. Richardson, John C. Davis, Timothy W. Behrens, Michael J. Townsend	2015	104
15	Etrolizumab Treatment Modulates MAdCAM-1 Levels in Serum in Ulcerative Colitis Patients The American Journal of Gastroenterology ·Franklin Fuh, Rich Erickson, Fuga Mayuzumi, Meina Tang, Romeo Maciuca, Mary Keir, Séverine Vermeire, Sharon O’Byrne, Teresa Ramirez‐Montagut	2015	3
16	Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production Science Translational Medicine ·Gail M. Gauvreau, Jeffrey M. Harris, Louis‐Philippe Boulet, Heleen Scheerens, J Mark FitzGerald, Wendy S. Putnam, Donald W. Cockcroft, Beth E. Davis, Richard Leigh, Yanan Zheng, Barbro Dahlén, Yehong Wang, Romeo Maciuca, Irvin Mayers, X. Charlene Liao, Lawren C. Wu, John G. Matthews, Paul M. O’Byrne	2014	96
17	Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials Journal of Allergy and Clinical Immunology ·Nicola A. Hanania, Michael Noonan, Jonathan Corren, Phillip E. Korenblat, Yanan Zheng, Wendy S. Putnam, Elaine Murray, Marty Golubitsky, Heleen Scheerens, Romeo Maciuca, Sarah Gray, Ramona L. Doyle, Dana McClintock, John G. Matthews, Karl Yen	2014	18
18	Lupus Nephritis Clinical Journal of the American Society of Nephrology ·Brad H. Rovin, Samir V. Parikh, Lee A. Hebert, Tak Mao Chan, Chi Chiu Mok, Ellen M. Ginzler, Lai Seong Hooi, Paul Brunetta, Romeo Maciuca, Neil Solomons	2012	37
19	Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study Arthritis & Rheumatism ·Brad H. Rovin, Richard Furie, Kevin Latinis, R. John Looney, Fernando C. Fervenza, Jorge Sánchez‐Guerrero, Romeo Maciuca, David Zhang, Jay Garg, Paul Brunetta, Gerald B. Appel, (unknown) Hit paper breakdown →	2012	972
20	Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo‐controlled, double‐blind, dose‐escalation study Arthritis & Rheumatism ·Jacqueline McBride, Jenny Jiang, Alexander R. Abbas, Alyssa Morimoto, Jing Li, Romeo Maciuca, Michael J. Townsend, Daniel J. Wallace, William P. Kennedy, Jörn Drappa	2012	146

About Romeo Maciuca

Romeo Maciuca is a scholar working on Immunology and Allergy, Rheumatology, Nephrology, Immunology and Hepatology, having authored 29 papers that have together received 2.5k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (8 papers), Inflammatory Bowel Disease (7 papers), Asthma and respiratory diseases (7 papers), Allergic Rhinitis and Sensitization (5 papers), Microscopic Colitis (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Inhalation and Respiratory Drug Delivery (3 papers) and Renal Diseases and Glomerulopathies (3 papers). The work is most often cited by research in Rheumatology (1.6k citations), Immunology (1.3k citations), Nephrology (358 citations), Radiology, Nuclear Medicine and Imaging (753 citations) and Immunology and Allergy (197 citations). Romeo Maciuca has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Paul Brunetta, Richard Furie, Brad H. Rovin, Fernando C. Fervenza, Gerald B. Appel, Jorge Sánchez‐Guerrero, Jay Garg, R. John Looney, David Zhang and Kevin Latinis. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of Crohn s and Colitis, Gastroenterology, Neurology and The American Journal of Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact